Radiation therapy tailored to tumor biology for advanced breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of postoperative radiation therapy in patients with Stage III breast cancer who have metastasis to internal mammary or supraclavicular lymph nodes. It aims to adapt the total radiation dose based on the tumor's response to prior neoadjuvant chemotherapy. Key outcomes include 5-year disease-free survival, overall survival, locoregional recurrence rates, adverse events, and quality of life assessments using validated questionnaires. Participants will undergo thorough evaluations before and after treatment to assess their disease status and quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female with age 19 or older
* Metastasis to internal mammary and/or supraclavicular lymph nodes, assessed by radiological exams and/or biopsy
* Underwent neoadjuvant chemotherapy
* Pathologic confirmation of invasive breast cancer treated with breast conserving surgery or mastectomy
* Eastern Cooperative Oncology Group performance status 0-2
* Informed consent

Exclusion Criteria:

* Previous history of radiation therapy to the chest
* Distant metastasis

Where it's running

• Samsung Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Haeyoung Kim, MD, PhD — Samsung Medical Center
• Study coordinator: Haeyoung Kim, MD, PhD
• Email: haeyoung0131.kim@samsung.com
• Phone: 82-2-3410-2612

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Capecitabine for MRD-positive, resected ER+/HER2-negative breast cancer

  This Phase 2 trial tests whether taking capecitabine can help people with resected, ER-positive/HER2-negative breast cancer who still have molecular residual disease after standard therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT07631052

• Biobran (rice bran arabinoxylan) supplement to support breast cancer chemotherapy

  This will test whether taking 3 grams daily of Biobran for 24 weeks helps women with stage I–III breast cancer tolerate paclitaxel and doxorubicin chemotherapy and have fewer side effects.

  Recruiting China Medical University Hospital · Taichung and 1 other locations · NCT07503496

• Meaning-Centered Therapy for Latinos for adults with advanced cancer

  This study tests whether Meaning-Centered Psychotherapy for Latinos (MCP-L) can reduce anxiety and depression and improve quality of life compared with CBT in Spanish-speaking adults with advanced cancer.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York and 1 other locations · NCT07225309

• SBRT with intratumoural pembrolizumab before neoadjuvant chemotherapy for high-risk breast cancer

  This study will test whether a short course of focused radiation plus two injections of pembrolizumab into the tumor before chemotherapy helps people with high‑risk invasive breast cancer respond better to treatment.

  Recruiting Phase 2 London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London, Ontario and 1 other locations · NCT07188246

• Predicting how hormone therapy before surgery affects breast cancer

  This study is testing how hormone therapy before surgery can help people with early-stage breast cancer and what it means for their tumors.

  Recruiting Phase 2 George Washington University · Washington D.C., District of Columbia · NCT06806930

• Meal timing during cancer treatment for Alaska Native and American Indian patients

  This test will see if an 8-hour time-restricted eating schedule during neoadjuvant or adjuvant therapy helps Alaska Native and American Indian adults with rectal or certain breast cancers.

  Recruiting Fred Hutchinson Cancer Center · Anchorage, Alaska · NCT06802172

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.